

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
24 April 2025 (24.04.2025)



(10) International Publication Number
WO 2025/085474 A1

(51) International Patent Classification:

C07D 487/04 (2006.01) A61K 31/536 (2006.01)
C07D 519/00 (2006.01) A61K 31/517 (2006.01)
A61P 35/00 (2006.01) A61K 31/519 (2006.01)

RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/US2024/051504

(22) International Filing Date:

16 October 2024 (16.10.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/544,512 17 October 2023 (17.10.2023) US

(71) Applicant: SYNNOVATION THERAPEUTICS, INC.

[US/US]; 200 Powder Mill Road E500-1801, Wilmington, Delaware 19803 (US).

(72) Inventors: QI, Chao; c/o Synnovation Therapeutics, Inc.,

200 Powder Mill Road E500-1801, Wilmington, Delaware 19803 (US). ZHOU, Fei; c/o Synnovation Therapeutics, Inc., 200 Powder Mill Road E500-1801, Wilmington, Delaware 19803 (US). LI, Yu; c/o Synnovation Therapeutics, Inc., 200 Powder Mill Road E500-1801, Wilmington, Delaware 19803 (US). ZHENG, Hewen; c/o Synnovation Therapeutics, Inc., 200 Powder Mill Road E500-1801, Wilmington, Delaware 19803 (US). WU, Liangxing; c/o Synnovation Therapeutics, Inc., 200 Powder Mill Road E500-1801, Wilmington, Delaware 19803 (US). YAO, Wenqing; c/o Synnovation Therapeutics, Inc., 200 Powder Mill Road E500-1801, Wilmington, Delaware 19803 (US).

(74) Agent: DAVEY, Evan A. et al.; Fish & Richardson P.C.,

P.O. Box 1022, Minneapolis, Minnesota 55440-1022 (US).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

Published:

— with international search report (Art. 21(3))



WO 2025/085474 A1

(54) Title: 5-OXO-4,5-DIHYDROIMIDAZO[1,5-A]QUINAZOLINE COMPOUNDS AS PI3K[ALPHA] INHIBITORS

(57) Abstract: The present application provides tricyclic compounds that modulate the activity of the PI3K α , which are useful in the treatment of various diseases, including cancer.